Urinary bladder paraganglioma metastatic to the lung in a patient with SDHB gene mutation: A case report

Abstract

Introduction: Paragangliomas are tumors originating from the neural crest. Most of them are benign and arise from various locations in the body. Extra-adrenal paragangliomas arise as sporadic cases in most settings or as part of heredofamilial syndromes in about one-quarter of cases. Succinate dehydrogenase subunit B (SDHB) gene mutations are associated with an aggressive clinical disease course of pheochromocytoma/paraganglioma.
Methods: We present a 41-year-old male former smoker with a history of a growing right upper lung nodule on chest imaging. He had no cough or respiratory symptoms. Twenty-seven months prior, the patient underwent a cystoprostatectomy due to paraganglioma of the bladder. Genetic testing identified a pathogenic mutation in SDHB gene, c.166_170delCCTCA (p.Pro56Tyrfs*5). He underwent a wedge resection of the lung nodule.
Results: Sectioning of the lung wedge revealed a well-circumscribed, firm tan nodule. Microscopically there were nests of large neoplastic cells with round nuclei and eosinophilic granular cytoplasm. Tumor cells were positive for synaptophysin and chromogranin and negative for pan-cytokeratin. S-100 protein highlighted sustentacular cells. Morphologically, the pulmonary neoplasm was similar to the primary tumor of the bladder. These features are consistent with a bladder paraganglioma metastatic to the lung, in a background of a hereditary paraganglioma syndrome.
Conclusion: Extra-adrenal paraganglioma occurring in a setting of hereditary paraganglioma syndrome has a high risk of metastasis. Lifelong surveillance even after prompt resection of the primary tumor with negative margins is required to ensure early detection of metastasis and prevent complications associated with it.

Keywords

Heredofamilial / Metastasis / Paraganglioma / Pheochromocytoma / Succinate dehydrogenase B gene

CONFLICTS OF INTEREST DISCLOSURE

There is no conflict of interest.

References

[1] Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007; 92(3): 779-786. PMid: 17200167. https://doi.org/10.1210/jc.2006-2315

[2] Berends AMA, Buitenwerf E, de Krijger RR, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern Med. 2018; 51: 68-73. PMid: 29361475. https://doi.org/10.1016/j.ejim.2018.01.015

[3] Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019; 381(6): 552-565. PMid: 31390501.https://doi.org/10.1056/NEJMra1806651

[4] Vicha A, Zdenek M, Pacak K. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes. 2013; 20(3): 186-191. PMid: 23481210. https://doi.org/10.1097/MED.0b013e32835fcc45

[5] Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and overexpression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005; 14(15): 2231-2239. PMid: 15987702. https://doi.org/10.1093/hmg/ddi227

[6] Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolylhydroxylase. Cancer Cell. 2005; 7(1): 77-85. PMid: 15652751. https://doi.org/10.1016/j.ccr.2004.11.022

[7] Dahia PL. Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas. Ann N Y Acad Sci. 2006; 1073: 208-220. PMid: 17102089. https://doi.org/10.1196/annals.1353.023

[8] So JS, Epstein JI. GATA 3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod Pathol. 2013; 26; 1365-1370. PMid: 23599157. https://doi.org/10.1038/modpathol.2013.76

[9] Cho YY, Kwak MK, Lee SE, et al. A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score. Surgery. 2018; 164: 511-517. PMid: 29929757. https://doi.org/10.1016/j.surg.2018.05.001

[10] Fliedner SMJ, Lehnert H, Pacak K. Metastatic Paraganglioma. Semin Oncol. 2010; 37(6): 627-637. PMid: 21167381. https://doi.org/10.1053/j.seminoncol.2010.10.017

[11] Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012; 44: 328-333. PMid: 22328163. https://doi.org/10.1055/s-0031-1301302

[12] Burnichon N, Vescovo L, Amar L, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011; 20: 3974-3985. PMid: 21784903. https://doi.org/10.1093/hmg/ddr324

[13] Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007; 92(10): 3822-3828. PMid: 17652212. https://doi.org/10.1210/jc.2007-0709